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Aims Primary percutaneous coronary intervention (PPCI) is the optimal treatment for patients presenting with ST-elevation
myocardial infarction (STEMI). An elevated index of microcirculatory resistance (IMR) reflects microvascular function
and when measured after PPCI, it can predict an adverse clinical outcome.We measured coronary microvascular func-
tion in STEMI patients and compared sequential changes before and after stent implantation.
Methods
and results
In 85 STEMI patients, fractional flow reserve, coronary flow reserve, and IMR were measured using a pressure wire
(Certus, St Jude Medical, St Paul, MN, USA) immediately before and after stent implantation. Stenting significantly im-
proved all of the measured parameters of coronary physiology including IMR from 67.7 [interquartile range (IQR):
56.2–95.8] to 36.7 (IQR: 22.7–59.5), P, 0.001. However, after stenting, IMR remained elevated (.40) in 28
(32.9%) patients. In 15 of these patients (17.6% of the cohort), only a partial reduction in IMR occurred and these pa-
tients were more likely to be late presenters (pain to wire time .6 h). The extent of jeopardized myocardium [stan-
dardized beta: 20.26 (IMR unit/Bypass Angioplasty Revascularization Investigation score unit), P: 0.009] and
pre-stenting IMR [standardized beta: 20.34 (IMR unit), P: 0.001] predicted a reduction in IMR after stenting (DIMR ¼
post-stenting IMR2 pre-stenting IMR), whereas thrombotic burden [standardized beta: 0.24 (IMR unit/thrombus score
unit), P: 0.01] and deployed stent volume [standardized beta: 0.26 (IMR unit/mm3 of stent), P: 0.01] were associated with
a potentially deleterious increase in IMR.
Conclusion Improved perfusion of themyocardium by stent deployment during PPCI is not universal. The causes of impairedmicro-
vascular function at the completion of PPCI treatment are heterogeneous, but can reflect a later clinical presentation
and/or the location and extent of the thrombotic burden.
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Introduction
Rapid revascularization by primary percutaneous coronary inter-
vention (PPCI) with stenting is considered to be the treatment of
choice for patients with ST-elevation myocardial infarction (STE-
MI).1 However, immediate restoration of epicardial coronary artery
patency does not always translate into restoration of ‘normal’ myo-
cardial reperfusion, a phenomenon referred to as ‘no reflow’ and
associated with profound coronary microvascular injury.2
Various pharmacological and procedural strategies have been
proposed to minimize or prevent no reflow after stenting, with
often conflicting results in part because of methodological
limitations.3,4
Early identification of the subset of patients who are likely to ex-
perience suboptimal reperfusion would allow timely application of
adjunctive or alternative therapeutic strategies. Consequently, clear
understanding of the pathophysiology of the coronary microvascu-
lature during MI is a critical step to improve PPCI outcomes.
The index of microcirculatory resistance (IMR) is a readily avail-
able thermodilution-derived parameter,5 which reflects the status
of the coronary microvasculature. Index of microcirculatory resist-
ance measured immediately after PPCI has been shown to predict
infarct size and the occurrence of microvascular obstruction at
cardiac magnetic resonance.6,7 Moreover, it has been recently
demonstrated that a final IMR value of .40 after PPCI has prognos-
tic relevance being significantly associated with increased rates of
death and readmission for heart failure at 1 year.8
The assessment of coronary microcirculation before stenting and
its consequences represent a critical gap in our understanding.
Therefore, we aimed to systematically evaluate in STEMI patients
the impact of stent deployment on coronary microvascular function
and to ascertain which factors might predict a suboptimal outcome
defined as a post-procedural IMR of .40.
Methods
Patients with STEMI admitted to the Oxford Heart Centre for PPCI
were prospectively considered for enrolment (Figure 1). ST elevation
myocardial infarction was defined as the occurrence of ongoing chest
pain for at least 30 min associated with ST-segment elevation .2 mm
in at least two contiguous leads. Exclusion criteria were symptom dur-
ation .12 h, the presence of severe haemodynamic instability, severe
left main disease, contraindications to adenosine infusion, plain old bal-
loon angioplasty (POBA) performance without stent implantation, and
inability to restore thrombolysis in myocardial infarction (TIMI) flow.2
before stenting. The local ethics committee approved the protocol and
the study was conducted in accordance with the Declaration of Helsinki.
This study population was recruited as part of the Oxford Acute
Myocardial Infarction (Ox-AMI) study (REC number 10/H0408/24).
Figure 1 Study flow chart.
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Primary percutaneous coronary intervention was performed accord-
ing to the international guidelines. Patients were on dual antiplatelet
therapy at the time of the procedure, usually loaded with 600 mg of clo-
pidogrel in the ambulance and 300 mg of aspirin. Anticoagulation was
achieved with unfractionated heparin (100 IU/kg to maintain an acti-
vated clotting time between 250 and 300 s) in combination with abcix-
imab (0.25 mg/kg intravenous bolus+ 0.125 mg/kg/min intravenous
continuous infusion for 12 h) or bivalirudin (0.75 mg/kg bolus followed
by an infusion of 1.75 mg/kg/min for up 4 h after the procedure as clin-
ically warranted). Abciximab was only used in combination with bivalir-
udin as a bailout strategy. Patients enrolled after January 2014 were
anticoagulated with bivalirudin and loaded with ticagrelor 180 mg if self-
presenters at the Acute and Emergency unit or reloaded with ticagrelor
180 mg at the end of the procedure if loaded with clopidogrel in the am-
bulance, reflecting changes in routine clinical practice in our institution.
Thrombus aspiration was recommended, but undertaken at the opera-
tor’s discretion.
Measurement of parameters of coronary
physiology
After crossing the culprit lesion, coronary flow was initially restored by
thrombus aspiration and/or balloon predilation. Before proceeding with
stenting, the pressure wire (Certus, St Jude Medical, St Paul, MN, USA)
was calibrated, equalized, and advanced towards the distal third of the
infarcted related artery. After intracoronary injection of 250 mg of iso-
sorbide dinitrate, the following baseline parameters were measured:
mean aortic pressure (Pa), mean distal pressure (Pd), and mean transit
time (mTt) calculated as the average three transit time measurements
during three separate intracoronary injections of 3 mL of room tem-
perature 0.9% saline solution. The same parameters were measured
again after hyperaemia, induced by an intravenous infusion of adenosine
at a rate of 140 mg/kg/min.
Fractional flow reserve (FFR), coronary flow reserve (CFR), and IMR
were calculated as previously described (see Supplementary material
online, Table S1).9 At this time, the initial procedural angioplasty wire
was removed and the pressure wire used for stent deployment. In 69
patients over 85, coronary wedge pressure (Pw) was measured during
stent balloon inflation and used to calculate the coronary wedge pres-
sure corrected IMR (IMRcorrected) value according to the following
formula: Pa × mTt × (Pd 2 Pw)/(Pa 2 Pw), with Pa, Pd, and mTt
measured during hyperaemia.10
Postdilation was left to the operator’s discretion. When the operator
was satisfied with the procedural result, Pa, Pd, mTt, FFR, CFR, and IMR
were measured again and variation in IMR after stenting (DIMR ¼
IMRpost-stenting 2 IMRpre-stenting) was determined. Before completion of
the procedure, the pressure wire was withdrawn back close to the guid-
ing catheter to exclude artefact due to pressure drift.
In 28 cases, it was not possible to obtain pre-stenting reproducible
and interpretable thermodilution curves. In all of these cases, TIMI
flow was ,3 and since unreliable values for CFR and IMR were ob-
tained, these patients were excluded from the study cohort (Figure 1).
Angiographic and electrocardiographic
analysis
Angiographic analysis was performed offline by two experienced opera-
tors blinded to coronary physiology indices—cases of disagreement
were resolved by consensus.
Angiographic area at risk was assessed by the Bypass Angioplasty Re-
vascularization Investigation (BARI) jeopardy score, as previously
described.11
Pre-stenting residual stenosis was measured by two-dimensional
quantitative coronary angiography (Medcon QCA software, Medcon
Limited, Tel Aviv, Israel). Angiographic thrombus burden was graded
from 0 to 5 by the thrombus score, as previously described12 (see
Supplementary material online, Table S2).
The stent after its deployment was approximated to a cylinder and
thus, stent volume was measured as p × (stent diameter/2)2 × stent
length. In case of overlapping stents, the final stent volume was ex-
pressed as the sum of individual stent volumes. Stent volume tertiles
were then calculated.
Pre-PPCI and final TIMI flow13 and post-procedural myocardial blush
grade (MBG) were assessed.14 Angiographic distal embolization was
defined as occurrence of distal filling defect with an abrupt ‘cut-off’
appearance in one or more peripheral coronary branches of the
infarcted-related artery, distal to the PPCI site.15
A 12-lead electrocardiogram was recorded at admission and 60 min
after PPCI in all patients and ST resolution (SSTR) calculated (see Sup-
plementary material online). No reflow was defined as the combination
of angiographic no reflow (final TIMI flow ,3 or TIMI flow 3 with MBG
,2) and/or incomplete post-procedural SSTR.16
Statistical analysis
All variables were expressed as mean and+standard deviation (SD) or
as median accompanied by interquartile range (IQR), as appropriate. In
detail, parameters of coronary physiology (FFR, CFR, and IMR) before
and after stenting are shown as median and IQR, as the Shapiro–Wilk
test showed that the data were non-normally distributed. To allow
the use of parametric techniques, base 10 logarithmic transformation
(Log (x) or Log(x + k), with k being a constant in case of x presenting
null or negative values) was applied.
Frequencies’ comparisons were made using x2 test or Fisher’s exact
test, as appropriate. Post hoc analysis of the x2 test was performed by
assessment of adjusted standardized residuals. Comparisons between
continuous variables were performed using T-test or analysis of variance
with Scheffe’s post hoc comparisons, as appropriate. Comparisons be-
fore and after stenting were performed by T-test for paired samples.
For multiple testing, the Benjamini and Hochberg method of Type 1
error control was applied and a P-value of ,0.01 was considered signifi-
cant.17 Correlations were assessed by Pearson’s R coefficient.
Independent predictors of DIMR, pre-stenting, and post-stenting IMR
≤40 were measured using the linear regression model and the multi-
variable binary logistic regression model, respectively (for further de-
tails, see Supplementary material online).
Statistical analysis was performed using SPSS 22.0 (SPSS, Inc., Chicago,
IL, USA) and P-values ,0.05 were considered statistically significant.
Results
Clinical and procedural characteristics
Eighty-five consecutive patients with STEMI were recruited in two
sequential periods from October 2010 to October 2014. Clinical
and procedural characteristics are summarized in Tables 1 and 2
and stratified according to post-stenting IMR (Tables 1 and 2). Strati-
fication according to pre-stenting IMR is reported in Supplementary
material online, Tables S3 and S4. The threshold for IMR .40, pre-
viously validated for post-stenting IMR, was adopted to delineate the
groups both before and after stenting.
Fifty-one patients (60%) presented a pre-stenting IMR of .40. In
this group, pain to wire time was longer, infarct size measured by
troponin AUC was larger, and more patients had TIMI flow 0 at
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Table 1 Clinical characteristics
Whole cohort
(85 patients)
Post-stent IMR ≤40
(57 patients)
Post-stent IMR >40
(28 patients)
P-values
Male gender 71 (83.5) 47 (82.4) 24 (85.7) 0.70
Age 60.2+10.3 58.5+10.5 63.6+9.0 0.03
Hypertension 42 (49.4) 29 (50.9) 13 (46.4) 0.70
Hypercholesterolaemia 37 (43.5) 27 (47.4) 10 (35.7) 0.31
Diabetes mellitus 31 (36.5) 24 (42.1) 7 (25.0) 0.12
Active smoker 48 (56.5) 33 (57.9) 15 (53.6) 0.71
Family history of IHD 43 (50.6) 30 (52.6) 13 0.59
Previous cardiological history 44 (51.8) 32 (56.1) 12 (42.8) 0.25
Pain to wire time
,3 h 44 (51.8) 35 (61.4) 9 (32.1) 0.01
≥3 and ,6 h 24 (28.2) 15 (26.3) 9 (32.1)
≥6 h 17 (20.0) 7 (12.3) 10 (35.8)
Culprit vessel
LAD 38 (44.7) 25 (43.8) 13 (46.4) 0.59
LCx 6 (7.1) 3 (5.3) 3 (10.7)
RCA 41 (48.2) 29 (50.9) 12 (42.9)
TIMI flow at presentation
0 64 (75.3) 41 (71.9) 23 (82.1) 0.23
1 4 (4.7) 2 (3.5) 2 (7.1)
2 10 (11.8) 7 (12.3) 3 (10.8)
3 7 (8.2) 7 (12.3) 0 (0.0)
Vessel closed at presentation 64 (75.3) 41 (71.9) 23 (82.1) 0.36
Thrombus score
0–1–2 14 (16.5) 10 (17.5) 4 (14.2) <0.001
3 20 (23.5) 16 (28.1) 4 (14.2)
4 43 (50.6) 31 (54.4) 12 (43.0)
5 8 (9.4) 0 (0.0) 8 (28.6)
Rentrop score
0 65 (76.5) 43 (75.4) 22 (78.7) 0.85
1 11 (12.9) 7 (12.3) 4 (14.2)
2 8 (9.4) 6 (10.5) 2 (7.1)
3 1 (1.2) 1 (1.8) 0 (0.0)
Number vessel disease
1 52 (61.2) 36 (63.1) 16 (57.2) 0.69
2 19 (22.3) 13 (22.8) 6 (21.4)
3 14 (16.5) 8 (14.1) 6 (21.4)
Syntax score 8.0 (4.0–13.0) 8.0 (4.0–11.0) 8.5 (5.0–13.7) 0.58
BARI Jeopardy score 31.0 (23.7–35.0) 31.0 (25.0–35.5) 29.7 (19.4–33.2) 0.11
Troponin peak (ng/mL) 86.1 (34.2–223.9) 51.5 (30.1–176.0) 139.5 (43.9–284.6) 0.01
Troponin AUC 144.2 (52.9–307.6) 87.5 (31.6–210.3) 246.5 (75.6–419.9) 0.008
Creatinine (mmol/mL) 77.6+27.1 75.2+18.5 82.70+39.7 0.23
Periprocedural medications
Aspirin 85 (100.0) 57 (100.0) 28 (100.0) 1.00
Clopidogrel 81 (95.3) 56 (98.2) 25 (92.6) 0.07
Ticagrelor 4 (4.7) 1 (1.8) 3 (7.4) 0.07
Heparin 39 (45.9) 29 (50.9) 10 (35.7) 0.19
Bivalirudin 51 (60.0) 31 (54.4) 20 (71.4) 0.13
GPIIbIIIa inhibitors
Total adopted 39 (45.9) 26 (45.6) 13 (46.4) 0.94
Bailout 10 (11.8) 4 (7.0) 6 (21.4) 0.05
Continued
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presentation. The remaining clinical characteristics were homoge-
neously distributed (see Supplementary material online, Tables S3
and S4).
After coronary stenting, 28 patients (32.9%) had an IMR of .40.
These patients were more likely to have larger infarct size, a longer
pain to wire time, a higher thrombotic burden, and worse indices of
myocardial reperfusion compared with those patients with a final
IMR of ≤40 (Tables 1 and 2).
Indices of coronary physiology
Parameters of coronary physiology before and after stenting, includ-
ing mean Pa, mean Pd, mTt at both baseline and after hyperaemia
induction, FFR, CFR, and IMR, are summarized in Table 3 and strati-
fied according to a post-stenting IMR value of 40 (Table 3). Stratifi-
cation according to pre-stenting IMR below or above 40 is
presented in Supplementary material online, Table S5.
Patients with a post-stenting IMR of .40 presented with a signifi-
cantly higher pre-stenting IMR value [68.5 (46.4–101.4) vs. 40.1
(24.5–61.6), P, 0.001]. Final CFR was lower in patients with post-
stenting IMR .40 [1.18 (0.89 21.56) vs. 1.51 (1.18–2.21), P: 0.003]
and accordingly a significant relationship was observed between
CFR and IMR in both pre-stenting (R coefficient: 20.35 P: 0.001)
and post-stenting (R coefficient: 20.32; P: 0.003).
Notably, a significant correlation was observed between mea-
sured pre-stenting IMR and pre-stenting IMRcorrected (R: 0.95,
P, 0.001; see Supplementary material online, Figure S1).
Change of coronary physiology after
stenting
In the whole cohort of 85 patients, stenting was associated with an
overall improvement of all the measured indices of coronary physi-
ology (Figure 2). Mean Pd at hyperaemia was significantly improved
after stenting from 58.0 (48.0–73.0) to 75.0 (64.0–86.0) mmHg,
P, 0.001 (Figure 2A), and similarly hyperaemic mTt was reduced
from 0.86 (0.49–1.38) to 0.43 (0.24–0.67) s (P, 0.001;
Figure 2B). As expected, both FFR [from 0.74 (0.61–0.88) to 0.94
(0.90–0.98), P, 0.001] and CFR [from 1.20 (0.96–1.62) to 1.35
(1.10–2.00), P, 0.001] improved after stenting (Figure 2C and D).
Interestingly, a significant IMR reduction [from 49.7 (29.4–78.4)
to 29.2 (18.9–54.3), P, 0.001] was observed after stenting
(Figure 2E), and this significant trend was confirmed also in
IMRcorrected [from 41.7 (25.0–67.4) to 27.9 (18.3–50.9), P: 0.01]
in the subgroup of 69 patients with coronary Pw measurement
(Figure 2F ).
At multivariable logistic regression analysis, thrombotic burden
[odds ratio (OR) 2.82; 95% CI 1.35–5.88, P: 0.006] and pre-stenting
IMR .40 (OR 1.03; 95% CI 1.01–1.05, P: 0.007) were the best pre-
dictors of post-stenting IMR .40 (R2 for the model: 0.30, c-statistic
0.76; Table 4), whereas longer pain to wire time (OR 9.74; 95% CI
3.35–28.34, P, 0.001) and TIMI flow 0 at presentation (10.72; 95%
CI 1.86–30.29, P: 0.008) were the only independent predictors of a
pre-stenting IMR of .40 (R2 for the model: 0.48, c-statistic 0.83; see
Supplementary material online, Table S6).
Interestingly, linear regression analysis of independent predictors
of change in IMR, expressed as DIMR, identified the extent of jeo-
pardized myocardium [standardized beta coefficient 20.26 (IMR
unit/BARI score unit), P: 0.009], the thrombotic burden [stan-
dardized beta coefficient 0.24 (IMR unit/thrombus score unit),
P: 0.01], stent volume [standardized beta coefficient 0.26 (IMR
unit/mm3 of stent), P: 0.01], and pre-stenting IMR .40 [standar-
dized beta coefficient: 20.34 (IMR unit), P: 0.001; R2 for the model:
0.38; Table 5]. The choice of anticoagulation strategy and the per-
formance of thrombus aspiration appeared to have no impact on
either the initial or the final IMR.
Evolution of coronary physiology
according to pre-stenting index of
microcirculatory resistance and patterns
of index of microcirculatory resistance
changes after stenting
The change in coronary physiology indices between patients with
pre-stenting IMR ≤40 and .40 was compared. A significant
improvement in parameters directly affected by epicardial sten-
osis, such as hyperaemic Pd and FFR, was observed after stenting
in both groups (Figure 3A and C ). Conversely, a significant im-
provement in parameters directly reflecting microvascular func-
tion, such as hyperaemic mTt [from 1.34 (0.97–1.81) to 0.73
(0.50–1.12) s, P, 0.001], CFR [from 1.06 (0.79–1.28) to 1.35
(1.02–1.90), P, 0.001], and IMR [from 67.7 (56.2–95.8) to 36.7
(22.7–59.5), P, 0.001], was observed only in the group of patients
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Table 1 Continued
Whole cohort
(85 patients)
Post-stent IMR ≤40
(57 patients)
Post-stent IMR >40
(28 patients)
P-values
GPIIbIIIa
inhibitors + bivalirudin
10 (11.8) 4 (7.0) 6 (21.4) 0.05
GPIIbIIIa inhibitors + heparin 29 (34.1) 22 (38.6) 7 (25.0) 0.05
Continuous normally distributed variables are presented as mean+ standard deviation. Continuous not-normally distributed variables are presented as median (interquartile
range). Frequencies are expressed as number (percentage). Frequencies are compared by application of x2 test or Fisher’s exact test. Continuous normally distributed variables
(e.g. age and creatinine) are compared by application of unpaired T-test. Continuous not-normally distributed variables are compared by application of unpaired T-test after
logarithmic transformation.
BARI, Bypass Angioplasty Revascularization Investigation; GPIIbIIIa, glycoprotein IIbIIIa; IHD, ischaemic heart disease; IMR, index of microcirculatory resistance; LAD, left anterior
descending; LCx, left circumflex; RCA, right coronary artery; TIMI, thrombolysis in myocardial infarction.
P-value ,0.01 considered statistically significant. The values of P, 0.05 are denoted as bold numbers.
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with a pre-stenting IMR of.40, whereas no significant changes after
stenting was observed in the group of patients with pre-stenting
IMR ≤40 [mTt from 0.43 (0.31–0.60) to 0.28 (0.21–0.50),
P: 0.21; CFR from 1.68 (1.18–2.04) to 1.40 (1.12–2.21), P: 0.68;
IMR from 27.1 (19.8 –35.8) to 22.7 (14.7 –35.4), P: 0.67]
(Figure 3B, D, and E).
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Table 2 Procedural characteristics
Whole cohort
(85 patients)
Post-stent IMR ≤40
(57 patients)
Post-stent IMR >40
(28 patients)
P-values
Thrombus aspiration 69 (81.2) 46 (80.7) 23 (82.1) 0.87
Predilation 85 (100.0) 57 (100.0) 28 (100.0) 1.00
Maximum balloon diameter (mm) 2.5+0.3 2.5+0.3 2.4+0.4 0.39
Pre-stent 2D-QCA
MLD (mm) 1.30+0.46 1.29+0.46 1.30+0.46 0.97
%DS 52.9+14.4 53.3+13.8 52.1+15.7 0.71
Lesion length (mm) 15.3 (11.0–21.2) 15.2 (11.5–23.3) 16.4 (10.3–20.6) 0.58
DES 76 (89.4) 48 (84.2) 28 (100.0) 0.02
Second generation 74 (87.0) 47 (82.4) 27 (96.4) 0.70
PES 2 (2.3) 1 (1.7) 1 (3.6) 0.85
EES 72 (84.7) 46 (80.7) 26 (92.8)
ZES 2 (2.3) 1 (1.7) 1 (3.6)
Number of stents
1 67 (78.8) 46 (80.7) 21 (75.0) 0.83
2 13 (15.3) 8 (14.0) 5 (17.8)
3 5 (5.9) 3 (5.3) 2 (7.2)
Stent length (mm) 28.0 (20.0–48.0) 24.0 (20.0–32.0) 28.0 (20.0–47.0) 0.55
Stent diameter (mm) 3.5 (3.0–4.0) 3.5 (3.0–4.0) 3.3 (3.0–4.0) 0.29
Stent volume (mm3)
First tertile 26 (30.6) 18 (31.6) 9 (32.1) 0.21
Second tertile 31 (36.5) 24 (42.1) 7 (25.0)
Third tertile 28 (32.9) 15 (26.3) 12 (42.9)
Postdilation 57 (67.0) 37 (64.9) 20 (71.4) 0.55
Number of postdilations 2.0 (1.0–3.0) 2.0 (1.7–3.0) 2.0 (1.0–4.5) 0.67
Maximum postdilation pressure (atm) 16.3+2.9 15.9+2.7 16.9+3.2 0.28
Maximum balloon diameter (mm) 4.0 (3.5–4.0) 4.0 (3.5–4.0) 3.5 (3.1–4.0) 0.35
Final TIMI flow
0 0 (0.0) 0 (0.0) 0 (0.0) <0.001
1 3 (3.6) 0 (0.0) 3 (10.8)
2 6 (7.0) 0 (0.0) 6 (21.4)
3 76 (89.4) 57 (100.0) 19 (67.8)
MBG
0–1 14 (16.5) 0 (0.0) 14 (50.0) <0.001
2 23 (27.0) 14 (24.6) 9 (32.1)
3 48 (56.5) 43 (75.4) 5 (17.9)
Incomplete
∑
STR (,70%) 15 (17.6) 0 (0.0) 15 (53.6) <0.001
Angiographic distal embolization 13 (15.3) 0 (0.0) 13 (46.4) <0.001
Angiographic no reflow (TIMI ,3 or TIMI 3
with MBG ,2)
18 (21.2) 0 (0.0) 18 (64.3) <0.001
Angiographic and ECG no reflow 22 (25.9) 0 (0.0) 22 (78.6) <0.001
Continuous normally distributed variables are presented as mean+ standard deviation. Continuous not-normally distributed variables are presented as median (interquartile
range). Frequencies are expressed as number (percentage). Frequencies are compared by application of x2 test or Fisher’s exact test. Continuous variables normally distributed
(e.g. maximum balloon diameter, MLD, and %DS) are compared by application of unpaired T-test. Continuous variables not-normally distributed are compared by application of
unpaired T-test after logarithmic transformation.
DES, drug-eluting stent; ECG, electrocardiographic; IMR, index of microcirculatory resistance; MBG, myocardial blush grade; MLD, minimal lumen diameter; TIMI, thrombolysis
in myocardial infarction; 2D-QCA, two-dimensional quantitative coronary angiography; %DS, percentage of diameter stenosis;
∑
STR, ST resolution; PES, paclitaxel eluting stent;
EES, everolimus eluting stent; ZES, zotarolimis eluting stent.
P-value ,0.01 considered statistically significant. The values of P, 0.05 are denoted as bold numbers.
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Table 3 Coronary physiology indices
Whole cohort (85 patients) Post-stent IMR ≤40 (57 patients) Post-stent IMR >40 (28 patients) P-values
Pre-stenting
Baseline
Pa (mmHg) 88.0 (74.0–97.0) 85.0 (73.0–94.0) 93.0 (86.0–105.0) 0.01
Pd (mmHg) 67.0 (58.0–83.0) 64.0 (56.0–81.0) 77.0 (61.0–94.0) 0.02
mTt (s) 1.12 (0.65–1.59) 0.89 (0.59–1.47) 1.43 (1.02–1.87) 0.002
Pd/Pa 0.83 (0.71–0.93) 0.81 (0.70–0.92) 0.85 (0.74–0.94) 0.37
Hyperaemia
Pa (mmHg) 83.0 (70.0–96.0) 80.0 (69.0–94.0) 84.0 (81.0–103.0) 0.07
Pd (mmHg) 58.0 (48.0–73.0) 55.0 (43.0–70.0) 65.0 (53.0–82.0) 0.01
mTt (s) 0.86 (0.49–1.38) 0.74 (0.41–1.29) 1.30 (0.67–1.54) 0.02
FFR 0.74 (0.61–0.88) 0.74 (0.57–0.84) 0.77 (0.65–0.90) 0.18
IMR 49.7 (29.4–78.4) 40.1 (24.5–61.6) 68.5 (46.4–101.4) <0.001
CFR 1.20 (0.96–1.62) 1.20 (0.87–1.76) 1.16 (0.99–1.43) 0.80
Post-stenting
Baseline
Pa (mmHg) 90.0 (79.0–105.0) 86.0 (76.0–102.0) 100.0 (88.0–110.0) 0.02
Pd (mmHg) 87.0 (78.0–99.0) 84.0 (75.0–93.0) 96.0 (85.0 0.107.0) 0.004
mTt (s) 0.66 (0.33–0.95) 0.53 (0.30–0.74) 1.09 (0.71–1.77) 0.03
Pd/Pa 0.97 (0.93–1.00) 0.95 (0.93–0.99) 0.99 (0.96–1.00) 0.03
Hyperaemia
Pa (mmHg) 80.0 (69.0–91.0) 77.0 (68.0–86.0) 87.0 (74.0–100.0) 0.01
Pd (mmHg) 75.0 (64.0–86.0) 73.0 (62.0–80.0) 83.0 (68.0–93.0) 0.004
mTt (s) 0.43 (0.24–0.67) 0.28 (0.22–0.44) 0.85 (0.64–1.80) <0.001
FFR 0.94 (0.90–0.98) 0.93 (0.89–0.98) 0.95 (0.91–0.99) 0.29
IMR 29.2 (18.9–54.3) 21.1 (15.5–29.4) 65.9 (54.1–128.6) <0.001
CFR 1.35 (1.10–2.00) 1.51 (1.18–2.21) 1.18 (0.89–1.56) 0.003
DIMR(post-stenting2 pre-stenting) 218.7 (237.6 2 3.97) 220.8 (239.4 2 4.1) 21.7 (226.52 70.7) <0.001
Whole cohort (69 patients) Post-stent IMR ≤40 (49 patients) Post-stent IMR >40 (20 patients) P-values
Pre-stenting
Coronary Pw (mmHg) 20.0 (15.5–26.0) 20.0 (14.0–24.0) 22.0 (20.0–29.0) <0.003
IMRcorrected 41.7 (25.0–67.4) 31.0 (20.8–57.7) 59.0 (40.5–86.5) <0.001
Post-stenting
IMRcorrected 27.9 (18.3–50.9) 21.9 (15.0–28.9) 64.0 (51.2–113.4) <0.001
DIMRcorrected 26.6 (225.7 2 5.3) 212.9 (229.2 2 1.2) 3.53 (215.72 63.5) <0.001
All variables are continuous not-normally distributed variables and presented as median (interquartile range). Comparisons have been performed by application of unpaired T-test after logarithmic transformation.
CFR, coronary flow reserve; Pw, wedge pressure; FFR, fractional flow reserve; IMR, index of microcirculatory resistance; IMRcorrected, coronary wedge pressure corrected IMR; mTt, mean transit time; Pa, aortic pressure; Pd, distal pressure.
P-value ,0.01 considered statistically significant. The values of P, 0.05 are denoted as bold numbers.
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Three different patterns of IMR evolution after stenting were ar-
bitrarily categorized (Figure 4): Good responders (n ¼ 57 patients,
67% of the whole cohort) defined as patients with a final post-
stenting IMR of ≤40 [IMR changed from 40.1 (24.5–61.6) to 22.1
(15.5–29.9), P, 0.001 Figure 4A]; partial responders (n ¼ 15 pa-
tients, 17.6% of the whole cohort) were those with a pre-stenting
IMR of .40 and a post-stenting IMR still of .40 [IMR changed
from 80.6 (66.4–100.9) to 55.5 (51.4–61.2), P, 0.001; Figure 4B];
poor responders (n ¼ 13 patients, 15.4% of the whole cohort)
were patients with an increase in IMR and a final IMR of .40 after
implantation of the stent [IMR changed from 45.7 (31.1–120.9) to
129.3 (90.9–231.8), P: 0.001; Figure 4C].
Interestingly, review of the clinical/procedural characteristics of
these patient groups demonstrated that poor responders presented
with a significantly higher thrombotic burden and underwent a
higher volume of stent implantation with a high incidence of angio-
graphic distal embolization, compared with both good and partial re-
sponders (Table 6). Conversely, partial responders had significantly
longer pain to wire time and thus higher pre-stenting IMR, com-
pared with good responders (Table 6). Ultimately, 82.3% (28/34)
of patients presenting with a pre-stenting IMR of ≤40 and 56.9%
(29/51) of those with a pre-stenting IMR of .40 resulted to be
good responders to stenting.
Discussion
This study demonstrates that the implantation of a coronary stent in
patients presenting with STEMI usually leads to an improvement in
microvascular function and a reduction in the measured IMR.
However, one-third of patients in this study population had evi-
dence of impaired microvascular function at completion of the
revascularization procedure with an IMR of .40 after stent
implantation. In some patients, this suboptimal outcome reflected
an incomplete normalization of an elevated IMR, and these patients
were more commonly late clinical presenters with longer ischaemic
times. However, in another subgroup of patients with a final IMR of
.40, an increase in IMR was observed after stent implantation,
which was associated with a larger thrombotic burden and/or higher
implanted stent volume.
Complete and timely restoration of myocardial perfusion is the
main aim in the treatment of STEMI patients and coronary stenting
is regarded as optimal therapy for most patients. This study shows
that when coronary microvascular function is measured invasively in
STEMI, implantation of a coronary stent lowers the IMR of ,40 in
approximately half of the patients presenting for treatment. This im-
provement in the parameters of coronary physiology after stenting
included an increase in mean Pd and FFR, parameters known to be
directly affected by the presence of an epicardial coronary stenosis,
and an improvement in parameters reflecting microcirculatory sta-
tus and myocardial reperfusion. However, despite optimal stent im-
plantation, many STEMI patients still have significant microvascular
obstruction and/or dysfunction. This series demonstrates that meas-
urement of IMR, immediately after coronary flow has been resumed,
is possible in most STEMI patients, but wewere unable to measure a
numerical IMR in some patients whowere potentially eligible for the
study. Ultimately, these patients had to be excluded from our sub-
sequent analysis and consequently, the observed study cohort prob-
ably underestimates the absolute extent of persistent microvascular
Figure 2 Evolution of coronary physiology indices after stenting in the whole patient cohort. Stenting in primary percutaneous coronary inter-
vention is associated with an improvement in all indices of coronary physiology, both those strictly associated with the presence of the pre-pro-
cedural epicardial stenosis [mean distal pressure (Pd, A) and fractional flow reserve (FFR, C)], and those reflecting microvascular status [mean
transit time (mTt, B), coronary flow reserve (CFR, D), and index of microcirculatory resistance measured and corrected (IMR and IMRcorrected,
E and F)].
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Table 4 Predictors of post-stenting index of microcirculatory resistance >40
Univariable analysis Multivariable analysis
OR (95% CI) P-values OR (95% CI) P-values
Age 1.05 (1.01–1.11) 0.03 1.04 (0.99–1.11) 0.13
Gender male 0.78 (0.22–2.76) 0.70 — —
Diabetes 0.46 (0.17–1.25) 0.13 — —
Hypertension 0.84 (0.34–2.07) 0.70 — —
Pain to wire time 1.01 (1.01–1.03) 0.05 1.38 (0.64–2.96) 0.41
Culprit vessel (LAD vs. non-LAD) 1.11 (0.45–2.75) 0.82 — —
BARI jeopardy score 0.96 (0.90–1.01) 0.14 — —
TIMI flow 0 at presentation 1.78 (0.52–6.04) 0.36 — —
MLD 1.02 (0.38–2.75) 0.97 — —
DS% 0.99 (0.96–1.03) 0.71 — —
Lesion length 0.98 (0.92–1.04) 0.45 — —
Thrombus score 2.04 (1.12–3.71) 0.02 2.82 (1.35–5.88) 0.006
Thrombus aspiration 1.10 (0.34–3.54) 0.87 — —
Stent volume 1.00 (0.99–1.01) 0.58 — —
Postdilation 1.35 (0.5–3.61) 0.55 — —
Upstream GPIIbIIIa inhibitors 0.54 (0.21–1.36) 0.19 — —
Pre-stent IMR .40 1.03 (1.01–1.04) 0.001 1.03 (1.01–1.05) 0.007
BARI, Bypass Angioplasty Revascularization Investigation; DS%, percentage diameter stenosis; GPIIbIIIa, glycoprotein IIbIIIa; IMR, index of microcirculatory resistance; LAD, left
anterior descending; MLD, minimal lumen diameter; OR, odds ratio; 95% CI, 95% confidence interval. The values of P, 0.05 are denoted as bold numbers.
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Table 5 Predictors of changes in the index of microcirculatory resistance
Univariable analysis Multivariable analysis
DIMR(post-stenting2 pre-stenting)
Beta (IMR unit)
P-value DIMR(post-stenting2 pre-stenting)
Beta (IMR unit)
P-value
Age (per year) 0.08 0.49 0.12 0.21
Gender male 0.15 0.18 0.05 0.62
Diabetes 20.23 0.03 20.08 0.36
Pain to wire time (per h) 20.21 0.06 — —
Culprit vessel
(LAD vs. non-LAD)
20.21 0.06 — —
BARI jeopardy score (BARI score unit) 20.22 0.04 20.26 0.009
TIMI flow 0 at presentation 0.03 0.76 — —
MLD (per mm) 0.08 0.45 — —
DS% (per % unit of diameter stenosis) 20.01 0.97 — —
Lesion length (per mm) 0.03 0.81 — —
Thrombus score (per unit of thrombus score) 0.27 0.01 0.24 0.01
Thrombus aspiration 20.10 0.54 — —
Stent volume (per mm3 of stent) 0.33 0.002 0.26 0.01
Postdilation 0.11 0.32 — —
Upstream GPIIbIIIa inhibitors 20.11 0.32 — —
Pre-stenting IMR .40 20.30 0.005 20.34 0.001
Correlation between dependent and independent variables expressed by standardized beta coefficient.
BARI, Bypass Angioplasty Revascularization Investigation; DS%, percentage of diameter stenosis; GPIIbIIIa, glycoprotein IIbIIIa; IMR, index of microcirculatory resistance; LAD, left
anterior descending; MLD, minimal lumen diameter; TIMI, thrombolysis in myocardial infarction. The values of P, 0.05 are denoted as bold numbers.
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dysfunction as this could approach 50% in an ‘all-comers’ STEMI
population.
Our results contrast with previous studies investigating IMR re-
sponses after stenting in elective stable patients. Aarnoudse et al.
and Yong et al. demonstrated that IMR was independent of epicar-
dial stenosis when coronary Pw was taken into account, and that
IMRcorrected was unchanged after stenting.
10,18 Even if the accuracy
of coronary Pw and collateral flow index has been debated in STEMI
patients,19 our larger study showed a strict relationship between
measured and IMRcorrected and a reduction in IMR after stenting in
this group of patients. This change in IMR was independent of re-
sidual epicardial stenosis before stenting, being independent of
FFR, percentage diameter stenosis, minimal lumen diameter, and le-
sion length (see Supplementary material online, Tables S4 and S5).
Obvious differences in the study populations are likely to explain
these apparently conflicting observations. In elective patients, the
IMR is lower, and the microcirculation is likely to be healthier and
will not change after stent deployment unless relevant distal embol-
ization occurs. In contrast, STEMI patients have a compromised
microcirculation on presentation, with limited flow in the infarct
zone and consequent impairment of both functional and structural
integrity of the coronary microvasculature.2 This is reflected by
higher values of measured IMR and IMRcorrected in STEMI than in
stable patients. Moreover, multivariable analysis demonstrates that
the only relevant predictors of pre-stenting IMR .40 were pain
towire time and TIMI flow at presentation reflecting the relationship
between IMR and the evolving microvascular dysfunction in
STEMI.20
Our results provide only minimal insights into the actual mechan-
isms accounting for IMR reduction after stenting in PPCI. However,
we hypothesize that in these clinical circumstances, the increase in
coronary flow after relief of the occlusion would probably lead to an
increased perfusion pressure and epicardial conductance (reflected
by Pd and FFR). Since microvascular tone depends on the upstream
driving pressure, a mechanical downstream relaxation of coronary
andmicrovascular tone, consequent to the release of vasoactive fac-
tors, with consequent reduction in microvascular resistance can be
hypothesized.21 This pressure dependence of microvascular resist-
ance has indeed been already described in the experimental setting,
with an increase in vessel diameter and a decrease in microvascular
resistance consequent to an increase in coronary pressure after re-
lief of an epicardial stenosis.22
A reduction in IMR after stenting, however, is not universal. Multi-
variable analysis showed that thrombotic burden with an OR of 2.82
and high pre-stenting IMR with an OR of 1.03 were the two main
predictors of an unfavourable IMR of .40 at the end of the proced-
ure. These results were confirmed and supplemented by the linear
regression analysis detecting the extent of jeopardized myocardium,
thrombotic burden, volume of stent implanted, and the pre-stenting
IMR as predictors of the degree of IMR change at completion of the
Figure 3 Evolution of indices of coronary physiology after stenting according to the pre-procedural microvasculature status, expressed by pre-
stenting index of microcirculatory resistance. Evolution of indices of coronary physiology is influenced by the status of the coronary microvascu-
lature before stenting. While indices mainly affected by the presence of epicardial stenosis [mean distal pressure (Pd, A) and fractional flow reserve
(FFR, C)] improve irrespectively of pre-stenting index of microcirculatory resistance, a significant improvement in mean transit time (mTt, B), cor-
onary flow reserve (CFR, D), and index of microcirculatory resistance measured and corrected (IMR and IMRcorrected, E and F) is observed after
stenting only in patients with pre-stenting IMR .40.
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procedure. Consequently, it is possible to surmise that the STEMI
patients most likely to benefit from stenting (and therefore most
likely to have a significant reduction in IMR after stenting) were
those with higher pre-stenting IMR, with a larger area of myocar-
dium at risk, a lower thrombotic burden, and requiring implantation
of a smaller stent to cover the disease.
Our data reflect previous literature describing a significant rela-
tionship between stent volume, e.g. plaque burden, and thrombotic
burden with distal embolization.23 Similarly, a larger area at risk im-
plies a larger area of potentially salvageable coronary microvascula-
ture with consequent potential higher reduction of microvascular
resistance after revascularization compared with treating a smaller
region of myocardium at risk.24
We have observed two principal mechanisms that result in a
raised final IMR. The first is probably related principally to the late
clinical presentation of the patient. Our data suggest that patients
with an initial IMR of .40 and a pain to wire time of .6 h were
at risk of a high final IMR. This is consistent with data demonstrating
the relationship between time to reperfusion and the occurrence of
myocardial haemorrhage seen as a marker of severe of microvascu-
lar injury.25 Currently, there are no proven particular treatment op-
tions for these late-presenting patients, but it is possible to speculate
that this could include novel therapies directed specifically at the mi-
crovasculature and/or myocardial repair.
The second mechanism, which resulted in a raised final IMR, re-
lates principally to distal embolization of the athero-thrombotic ma-
terial. Importantly, in this group of patients, IMR was ≤40 after
predilation and/or thrombectomy alone. A high final IMR after stent-
ing was consequent to a high thrombotic burden requiring a large
stent volume (upper tertile of stent volume, e.g. stent volume
.336 mm3; see Supplementary material online, Figure S2). These
data support the notion that stenting is a procedural step significant-
ly associated with distal embolization.26 These observations suggest
that this group of patients with extensive thrombus could benefit
from adjunctive strategies, e.g. further thrombus aspiration and/or
GPIIbIIIa inhibitors or perhaps a deferred stenting strategy.27
In conclusion, our data provide insights into the heterogeneity of
the response of microvasculature to stenting, allowing speculation
Figure 4 Patterns of index of microcirculatory resistance (IMR) response to stenting in primary percutaneous coronary intervention patients.
The graph shows the three possible patterns of index of microcirculatory resistance responses after stenting. Good responders presenting a final
favourable IMR of ≤40, partial responders presenting a significant reduction in index of microcirculatory resistance, but incomplete since the final
value will be still .40, and poor responders with a significant increase in index of microcirculatory resistance after stenting, ending with a final
value of .40.
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that using IMR prior to stent implantation, in combination with other
clinical and angiographic variables, could potentially facilitate the
triage of STEMI patients for consideration of novel therapies.
Limitations
In our study, we collected detailed coronary physiology data in a
large cohort of patients undergoing PPCI; in this emergency setting,
it is inevitable that some data will be unobtainable. This limitation
will affect any flow-dependant technique including use of the Dop-
pler wire. Theoretically, it could lead to selection bias, but it is not
unreasonable to assume that patients with pre-stenting TIMI flow
,3 would also have had a high pre-stenting IMR.
Onlymacroscopic angiographic distal embolizationwas considered
in the present study. Our data do not take into account the inevitable
role of microembolization that might contribute to explain the in-
complete reduction in IMR observed in partial responders to stenting.
Prospective validation of the prognostic value of IMR .40 is
awaited and currently, this arbitrary threshold has previously only
been described after completion of the interventional procedure.8
Angiography is inferior to intravascular ultrasound or optical co-
herence tomography in the assessment of thrombotic burden and
stent volume, particularly in case of overlapping stents when a de-
tailed measurement of the stent area would allow an accurate def-
inition of final stent volume.
Finally, in consideration of multiple comparisons testing, there is
potential for a type 1 error. However, the consistency of the rela-
tionships and highly significant P-values between indices of coronary
physiology and multiple important clinical variables suggest the
relevance of our findings.
Supplementary material
Supplementary material is available at European Heart Journal online.
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Table 6 Differences among good responders (post-stenting IMR ≤40), incomplete responders (post-stenting IMR >40,
though reduction), and poor responders (post-stenting IMR >40 with an increase)
Good responders
(57 patients)
Partial responders
(15 patients)
Poor responders
(13 patients)
Overall
P-values
Pre-stenting IMR 40.1 (24.5–61.6)a,b 80.6 (66.4–100.9)b 45.7 (31.1–120.9)a 0.001
Pre-stenting IMR ≤40 28 (49.1)c 0 (0.0)c 6 (46.1) 0.002
DIMR(post-stenting2 pre-senting) 220.8 (239.4 2 4.1)
b 226.4 (242.1 2 10.9)a 70.8 (17.12 101.7)a,b <0.001
Thrombus aspiration 46 (80.7) 12 (80.0) 11 (84.6) 0.94
GPIIbIIIa inhibitors 26 (45.6) 7 (46.7) 6 (46.1) 0.40
Pain to wire time
,3 h 35 (61.4)c 3 (20.0) 6 (46.1) 0.005
≥3 and ,6 h 15 (26.3) 4 (26.7) 5 (38.5)
≥6 h 7 (12.3) 8 (53.3)c 2 (15.4)
Thrombus score
0–1–2 6 (17.6) 3 (20.0) 1 (7.7) <0.001
3 8 (23.5) 2 (13.3) 2 (15.4)
4 17 (50.0) 9 (60.0) 3 (23.1)
5 3 (8.9) 1 (6.7) 7 (53.8)c
Stent volume
First tertile 17 (29.8) 6 (40.0) 3 (23.1) 0.03
Second tertile 24 (42.1) 6 (40.0) 1 (7.7)
Third tertile 16 (28.1) 3 (20.0) 9 (69.2)c
Angiographic distal
embolization
(0.0)c 0 (0.0) 13.0 (100.0)c <0.001
GPIIbIIIa, glycoprotein IIbIIIa; DIMR, variation in IMR; IMR, index of microcirculatory resistance.
a,bSignificant comparison at post-analysis test for ANOVA.
cCells with statistical significance after analysis of adjusted standardized residuals for x2 test. The values of P, 0.05 are denoted as bold numbers.
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